Diphtheria antitoxin for therapeutic use is in limited supply. A potential source might be affinity-purified antibodies originally derived from plasma of adults who received a booster dose of a vaccine containing diphtheria toxin. These antibodies might be useful for treating even severe cases of diphtheria.
Ahead of Print -Postbooster Antibodies from Humans as Source of Diphtheria Antitoxin - Volume 22, Number 7—July 2016 - Emerging Infectious Disease journal - CDC
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.